Use of a Novel Enhanced DNA Vaccine Vector for Preclinical Virus Vaccine Investigation

DNA vaccines are stable, safe, and cost effective to produce and relatively quick and easy to manufacture. However, to date, DNA vaccines have shown relatively poor immunogenicity in humans despite promising preclinical results. Consequently, a number of different approaches have been investigated t...

Full description

Bibliographic Details
Main Authors: Rosamund Chapman, Edward P. Rybicki
Format: Article
Language:English
Published: MDPI AG 2019-06-01
Series:Vaccines
Subjects:
Online Access:https://www.mdpi.com/2076-393X/7/2/50